{"id":"W1957081846","doi":"10.1111/j.1528-1167.2012.03441.x","title":"The urinary safety profile and secondary renal effects of retigabine (ezogabine): A first‐in‐class antiepileptic drug that targets KCNQ (K<sub>v</sub>7) potassium channels","year":2012,"lang":"en","type":"review","venue":"Epilepsia","topic":"Cardiac electrophysiology and arrhythmias","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"U.S. Food and Drug Administration; Valeant Pharmaceuticals International; GlaxoSmithKline","keywords":"Urinary system; Medicine; Adverse effect; Placebo; Clinical trial; Urology; Internal medicine; Anesthesia; Pharmacology; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001050668,0.0003997928,0.001071069,0.0009091552,0.0001655653,0.0005562407,0.0004120574,0.0004661684,0.00158974],"category_scores_gemma":[0.001862967,0.0001304909,0.001641647,0.0009299106,0.000174545,0.0003838685,0.00020862,0.0004864439,0.0002525879],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003650511,"about_ca_system_score_gemma":0.000805083,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009642376,"about_ca_topic_score_gemma":0.00244912,"domain_scores_codex":[0.9991845,0.0002680702,0.0001771258,0.00006505587,0.0002631499,0.0000420231],"domain_scores_gemma":[0.9981337,0.0008231658,0.0006778549,0.00002587745,0.0003078537,0.00003157964],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001007723,0.00008845933,0.00278525,0.08382306,0.001775547,0.000698204,0.0001646229,0.0006399734,0.008394064,0.001034267,0.01072312,0.8888657],"study_design_scores_gemma":[0.001109448,0.008419325,0.06891035,0.0377058,0.01610907,0.02127459,0.0005349153,0.001203982,0.02446915,0.002187738,0.8178946,0.0001810366],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.007101572,0.9896259,0.0005798281,0.0003613798,0.0000927748,0.00004936131,0.0002968134,0.00001970599,0.001872845],"genre_scores_gemma":[0.05117474,0.9448307,0.001134998,0.0009179668,0.0002480886,0.0000715288,0.0003913137,0.00000717471,0.001223554],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.00158974,"threshold_uncertainty_score":0.005556524,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01039958907160417,"score_gpt":0.2460240838909757,"score_spread":0.2356244948193715,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}